TATAA Biocenter and Strand Life Sciences Announce Strategic Partnership
News Jun 24, 2015
TATAA Biocenter has partnered with Strand Life Sciences to advance the analysis of Next Generation Sequencing (NGS) data.
As part of the partnership, TATAA Biocenter will distribute and support Strand NGS, Strand’s premier analysis tool for NGS data, in Europe. TATAA is also going to use Strand NGS in its popular NGS training courses.
“We always seek collaboration with the best solution providers for our training courses and Strand Life Sciences are top of the class for NGS whole transcriptome profiling”, says Kristina Lind, coordinator of TATAA Biocenter’s hands-on training program. “Our customers request professional tools for the entire NGS workflow from sample preparation, quality control, library preparation, sequencing and data analysis.”, says Mikael Kubista, president of TATAA Biocenter, “With Strand NGS our customers obtain the most comprehensive and powerful tool for the analysis of Next Generation Sequencing data”.
“We have always welcomed collaborations for serving the customer better and for the greater good of science. Tataa Biocenter is an established player in Europe with a wide reach. European customers will now have access to one of the most comprehensive, commercially available, NGS analysis tools” says Scott Storrer, President of Strand Life Science.
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE